Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 03/09/18

Kim Witherspoon

Kim Witherspoon

Senior Program Specialist, Biologist

Ms. Kim Witherspoon has been a part of the Cancer Therapy Evaluation Program (CTEP) since September 2000. She became part CTEPís Investigational Drug Branch (IDB) in February 2018. In IDB, Kim ensures compliance with NIH and NCI grant policy. She is Senior Program Specialist for the Experimental Therapeutics Clinical Trials Network (ETCTN). She performs duties as a Program Official, a Level II FAC-Contract Officer's Representative (COR), and Program Analyst. As a Program Official, her portfolio includes clinical research projects focused on bioethics.

Kim graduated from the University of Kansas in 1981 with a Bachelor of Science degree in Microbiology. After graduation, she worked as a Production Technician for Meloy Laboratories, a subsidiary of Revlon. In September 1982, Kim began her career as a federal government employee working for the Department of Defense. As a Biological Laboratory Technician in a Department of Medicine research laboratory at the Uniformed Services University of the Health Sciences (USUHS), she rapidly advanced to become the laboratory manager and co-author on a number of scientific publications. After 18 years of service at USUHS, she accepted a position as a Biologist in CTEP. Between 2009 and 2010 Kim received her dual Master degrees from the University of Maryland University College in Business Administration and Biotechnology specializing in Biodefense and Biosecurity.

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in 2014 after serving part time since 2012, and was appointed Branch Chief in 2018. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. Dr. Moscow completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…